Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk’s proprietary protein-acylation technology, and is administered using an injection device. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight. Once-weekly subcutaneous semaglutide has recently been approved in the US, Puerto Rico and Canada, and has received a positive opinion in the EU for the treatment of patients with type 2 diabetes. It will be launched as the Ozempic® Pen, a pre-filled device. Semaglutide is also under regulatory review in Japan and Switzerland for the treatment of type 2 diabetes. Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.
The preparation of this review was not supported by any external funding.
Compliance with Ethical Standards
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/DE1DF0600FB4A285.
- 2.US Department of Health an Human Services. New Drug Approval. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209637s000ltr.pdf. Accessed 15 Dec 2017.
- 3.Novo Nordisk. Ozempic® (semaglutide) approved in the US [media release]. 5 Dec. 2017. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2154210.html.
- 4.Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use: US prescribing Information. 2017. http://www.novo-pi.com/ozempic.pdf. www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Accessed 2017.
- 5.European Medicines Agency. Ozempic (semaglutide): opinion. 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004174/smops/Positive/human_smop_001235.jsp&mid=WC0b01ac058001d127. Accessed 20 Dec 2017.
- 6.Novo Nordisk. OZEMPIC® semaglutide injection—product monograph including patient medication information. 2018. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/ozempic-product-monograph.pdf. Accessed 11 Jan 2018.
- 7.Adis Insight. Drug profile: Semaglutide oral—Novo Nordisk. 2017. http://adisinsight.springer.com/drugs/800031465. Accessed 15 Dec 2017.
- 8.Adis Insight. Drug profile: Semaglutide transdermal—Novo Nordisk 2017. http://adisinsight.springer.com/drugs/800050528. Accessed 15 Dec 2017.
- 11.Raun K, Fels JJ, Rosenquist C, et al. Semaglutide, a once-weekly glucagon-like peptide 1 (GLP-1) analog, reduces bodyweight and promotes a more healthy food choice in diet-induced obese rats [abstract no. 1140-P]. Diabetes. 2015;64(Suppl 1):A293.Google Scholar
- 12.Rakipovski G, Rolin B, Kirk R, et al. Long-acting GLP-1 receptor agonists semaglutide and liraglutide protect against development of atherosclerosis in animal models independent of body-weight-lowering effects [abstract no. 244-OR]. Diabetes. 2017;66(Suppl 1):A64.Google Scholar
- 13.Demmel V, Sandberg-Schaal A, Jacobsen JB, et al. Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects [abstract no. P5349]. Eur Heart J. 2017;38(Suppl 1):1128–9.Google Scholar
- 16.Arold G, Kupcova V, Jensen L, et al. Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment [abstract no. 822]. Diabetologia. 2017;60(Suppl 1):S380–1.Google Scholar
- 19.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.CrossRefPubMedGoogle Scholar
- 20.Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–88.Google Scholar
- 21.Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.CrossRefPubMedGoogle Scholar
- 23.Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.CrossRefPubMedGoogle Scholar
- 24.Rodbard H, Lingvay I, Reed J, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5) [abstract no. 766]. Diabetologia. 2016;59(Suppl. 1):S364–5.Google Scholar
- 27.Novo Nordisk. Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial [media release]. 23 June 2017. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2115373.html.
- 28.Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13172.